[HTML] mdpi.com

[HTML][HTML] BET-inhibitor I-BET762 and PARP-inhibitor talazoparib synergy in small cell lung cancer cells

FP Fiorentino, I Marchesi, C Schröder… - International Journal of …, 2020 - mdpi.com
Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is
caused by frequent relapses and acquired resistance. Despite that several target-based …
被引用次数：28 相关文章
[PDF] academia.edu

[PDF][PDF] BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

FP Fiorentino, I Marchesi, C Schröder, R Schmidt… - Int. J. Mol. Sci, 2020 - academia.edu
Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is
caused by frequent relapses and acquired resistance. Despite that several target-based …

[引用][C] BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

FP Fiorentino, I Marchesi, C Schroder… - … Journal of Molecular …, 2020 - jglobal.jst.go.jp
BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer
Cells | Article Information | J-GLOBAL Art J-GLOBAL ID:202102286590355312 Reference …

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

FP Fiorentino, I Marchesi… - International …, 2020 - pubmed.ncbi.nlm.nih.gov
Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is
caused by frequent relapses and acquired resistance. Despite that several target-based …
[HTML] nih.gov

[HTML][HTML] BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

FP Fiorentino, I Marchesi, C Schröder… - … Journal of Molecular …, 2020 - ncbi.nlm.nih.gov
Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is
caused by frequent relapses and acquired resistance. Despite that several target-based …

BET-inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

FP Fiorentino, I Marchesi, C Schröder, R Schmidt… - 2020 - agris.fao.org
Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is
caused by frequent relapses and acquired resistance. Despite that several target-based …

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

FP Fiorentino, I Marchesi, C Schröder… - Int. J. Mol …, 2020 - search.proquest.com
Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is
caused by frequent relapses and acquired resistance. Despite that several target-based …

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells.

FP Fiorentino, I Marchesi, C Schröder… - International …, 2020 - search.ebscohost.com
Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is
caused by frequent relapses and acquired resistance. Despite that several target-based …

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells.

FP Fiorentino, I Marchesi, C Schröder… - … Journal of Molecular …, 2020 - europepmc.org
Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is
caused by frequent relapses and acquired resistance. Despite that several target-based …
[PDF] researchgate.net

[PDF][PDF] BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

FP Fiorentino, I Marchesi, C Schröder, R Schmidt… - Int. J. Mol …, 2020 - researchgate.net
Small cell lung cancer (SCLC) is an aggressive type of lung cancer with high mortality that is
caused by frequent relapses and acquired resistance. Despite that several target-based …